(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its specifically engineered HER2-directed DXd antibody drug conjugate Enhertu.
AstraZeneca said the trial showed that Enhertu, which was jointly developed and commercialised with Daiichi Sankyo, demonstrated a "statistically significant and...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE